Systematic Review of Prostate Cancer Drug Cost-Effectiveness

Wei Wang's systematic review analyzes 13 studies on the cost-effectiveness of degarelix and LHRH agonists for prostate cancer treatment. The review, covering literature up to December 2025, compares drugs like leuprorelin, goserelin, and triptorelin. It includes methodological details such as model frameworks, parameters, and uncertainty analyses from the selected studies.

Use Cases

• Compare cost-effectiveness outcomes for degarelix versus leuprorelin, goserelin, or triptorelin based on model parameters from 13 studies.
• Analyze the methodological variations and model frameworks, such as Markov models with 1 to 30-year time horizons, across the included pharmacoeconomic studies.
• Evaluate the geographic bias by comparing findings from the 7 studies based in developed countries to conclusions for low- and middle-income settings.
• Assess the reported cost-effectiveness of 6-month depot LHRH agonist formulations against monthly or 3-monthly counterparts using the summarized study data.

Strengths

• Includes 13 high-quality pharmacoeconomic studies evaluated with Quality of Health Economic Studies and Consolidated Health Economic Evaluation Reporting Standards.
• Provides comparative analysis of multiple drugs (degarelix, leuprorelin, goserelin, triptorelin) and their formulations (e.g., 6-month vs. 3-month depot).
• Summarizes key study aspects including model frameworks, parameters, and uncertainty analyses for methodological transparency.

Limitations

• Limited generalizability as evidence is predominantly derived from 7 studies in high-income countries.
• Significant methodological variations exist among the 13 included studies, complicating direct comparison.
• The dataset is a 154.5 KB document, representing a summary review rather than primary tabular data for computational analysis.

Provenance

Source

Wei Wang via figshare

Collection Method

Systematic review of databases including Embase, PubMed, Cochrane Library, CNKI, Web of Science, Scopus, and Tufts CEA Registry.

Time Range

Literature from database inception up to December 30, 2025.

Freshness

Literature coverage up to December 30, 2025, with last platform update on 2026-03-23.

Geography

Primarily developed countries (7 studies), including the United States, United Kingdom, and China.